nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—S100A13—cardiovascular system—attention deficit hyperactivity disorder	0.0417	0.0728	CbGeAlD
Amlexanox—S100A12—cardiovascular system—attention deficit hyperactivity disorder	0.0412	0.0718	CbGeAlD
Amlexanox—PDE4C—forebrain—attention deficit hyperactivity disorder	0.0369	0.0644	CbGeAlD
Amlexanox—FGF1—forebrain—attention deficit hyperactivity disorder	0.0304	0.053	CbGeAlD
Amlexanox—S100A13—nervous system—attention deficit hyperactivity disorder	0.0268	0.0467	CbGeAlD
Amlexanox—S100A12—Cytosolic sensors of pathogen-associated DNA—MB21D1—attention deficit hyperactivity disorder	0.0266	0.0624	CbGpPWpGaD
Amlexanox—S100A13—central nervous system—attention deficit hyperactivity disorder	0.0258	0.045	CbGeAlD
Amlexanox—FGF1—cardiovascular system—attention deficit hyperactivity disorder	0.0257	0.0448	CbGeAlD
Amlexanox—S100A13—cerebellum—attention deficit hyperactivity disorder	0.0252	0.044	CbGeAlD
Amlexanox—PDE4C—midbrain—attention deficit hyperactivity disorder	0.0244	0.0425	CbGeAlD
Amlexanox—S100A13—brain—attention deficit hyperactivity disorder	0.0205	0.0357	CbGeAlD
Amlexanox—S100A12—brain—attention deficit hyperactivity disorder	0.0202	0.0352	CbGeAlD
Amlexanox—FGF1—midbrain—attention deficit hyperactivity disorder	0.0201	0.035	CbGeAlD
Amlexanox—PDE4C—nervous system—attention deficit hyperactivity disorder	0.02	0.0349	CbGeAlD
Amlexanox—S100A12—Cytosolic sensors of pathogen-associated DNA—POLR3A—attention deficit hyperactivity disorder	0.0195	0.0458	CbGpPWpGaD
Amlexanox—PDE4C—central nervous system—attention deficit hyperactivity disorder	0.0193	0.0336	CbGeAlD
Amlexanox—PDE4B—forebrain—attention deficit hyperactivity disorder	0.0171	0.0299	CbGeAlD
Amlexanox—PDE4D—cerebellum—attention deficit hyperactivity disorder	0.0166	0.029	CbGeAlD
Amlexanox—FGF1—nervous system—attention deficit hyperactivity disorder	0.0165	0.0288	CbGeAlD
Amlexanox—FGF1—central nervous system—attention deficit hyperactivity disorder	0.0159	0.0277	CbGeAlD
Amlexanox—FGF1—cerebellum—attention deficit hyperactivity disorder	0.0155	0.0271	CbGeAlD
Amlexanox—PDE4C—brain—attention deficit hyperactivity disorder	0.0153	0.0267	CbGeAlD
Amlexanox—PDE4A—cerebellum—attention deficit hyperactivity disorder	0.0147	0.0256	CbGeAlD
Amlexanox—PDE4D—brain—attention deficit hyperactivity disorder	0.0135	0.0235	CbGeAlD
Amlexanox—FGF1—brain—attention deficit hyperactivity disorder	0.0126	0.022	CbGeAlD
Amlexanox—PDE4A—brain—attention deficit hyperactivity disorder	0.0119	0.0208	CbGeAlD
Amlexanox—PDE4B—midbrain—attention deficit hyperactivity disorder	0.0113	0.0197	CbGeAlD
Amlexanox—IL3—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.0105	0.0246	CbGpPWpGaD
Amlexanox—PDE4C—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.0105	0.0246	CbGpPWpGaD
Amlexanox—PDE4B—nervous system—attention deficit hyperactivity disorder	0.00931	0.0162	CbGeAlD
Amlexanox—PDE4D—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00912	0.0214	CbGpPWpGaD
Amlexanox—PDE4B—central nervous system—attention deficit hyperactivity disorder	0.00896	0.0156	CbGeAlD
Amlexanox—PDE4B—cerebellum—attention deficit hyperactivity disorder	0.00876	0.0153	CbGeAlD
Amlexanox—PDE4A—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00868	0.0203	CbGpPWpGaD
Amlexanox—PDE4B—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00803	0.0188	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00715	0.0168	CbGpPWpGaD
Amlexanox—PDE4B—brain—attention deficit hyperactivity disorder	0.00711	0.0124	CbGeAlD
Amlexanox—PDE4C—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.0059	0.0138	CbGpPWpGaD
Amlexanox—IL3—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00552	0.0129	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00542	0.0127	CbGpPWpGaD
Amlexanox—PDE4D—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00514	0.012	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0051	0.012	CbGpPWpGaD
Amlexanox—PDE4A—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00489	0.0115	CbGpPWpGaD
Amlexanox—IL3—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00473	0.0111	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.0047	0.011	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00464	0.0109	CbGpPWpGaD
Amlexanox—PDE4B—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00452	0.0106	CbGpPWpGaD
Amlexanox—S100A12—Cytosolic sensors of pathogen-associated DNA—EP300—attention deficit hyperactivity disorder	0.00397	0.00931	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00376	0.00882	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00345	0.00808	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00342	0.00803	CbGpPWpGaD
Amlexanox—IL3—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00341	0.008	CbGpPWpGaD
Amlexanox—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—attention deficit hyperactivity disorder	0.00341	0.00798	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00335	0.00786	CbGpPWpGaD
Amlexanox—IL3—Immune System—STUB1—attention deficit hyperactivity disorder	0.00331	0.00775	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00327	0.00767	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00311	0.00729	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00305	0.00714	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00297	0.00696	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00285	0.00667	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00285	0.00667	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00274	0.00642	CbGpPWpGaD
Amlexanox—S100A12—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00274	0.00641	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00271	0.00635	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00268	0.00629	CbGpPWpGaD
Amlexanox—S100A12—Immune System—STUB1—attention deficit hyperactivity disorder	0.00265	0.00621	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00259	0.00606	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00251	0.00588	CbGpPWpGaD
Amlexanox—IL3—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00251	0.00587	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.0025	0.00585	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00246	0.00577	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00232	0.00545	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00228	0.00534	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00219	0.00514	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00217	0.00508	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00215	0.00504	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00214	0.00501	CbGpPWpGaD
Amlexanox—IL3—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00212	0.00497	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00211	0.00495	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00203	0.00476	CbGpPWpGaD
Amlexanox—S100A12—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00201	0.00471	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00199	0.00467	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00197	0.00462	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00195	0.00457	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00191	0.00448	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00189	0.00443	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00187	0.00439	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00185	0.00433	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00184	0.00431	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00183	0.00429	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00182	0.00426	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0018	0.00422	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0018	0.00422	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00178	0.00417	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00178	0.00416	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00176	0.00414	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00175	0.00411	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00173	0.00407	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00172	0.00402	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0017	0.00398	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00168	0.00394	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00166	0.0039	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00165	0.00388	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00165	0.00387	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00165	0.00386	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00163	0.00383	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00162	0.00379	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00161	0.00378	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00156	0.00367	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00153	0.00358	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00153	0.00358	CbGpPWpGaD
Amlexanox—FGF1—Immune System—STUB1—attention deficit hyperactivity disorder	0.00151	0.00355	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.0015	0.00352	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0015	0.00351	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00149	0.00349	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00145	0.00341	CbGpPWpGaD
Amlexanox—FGF1—Disease—STUB1—attention deficit hyperactivity disorder	0.0014	0.00328	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00137	0.00321	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00135	0.00317	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00134	0.00315	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.0013	0.00305	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.0013	0.00304	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00125	0.00294	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00125	0.00292	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00123	0.00289	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00121	0.00284	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00119	0.0028	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00118	0.00277	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00118	0.00276	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00118	0.00276	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00117	0.00275	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00116	0.00272	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00115	0.0027	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00115	0.0027	CbGpPWpGaD
Amlexanox—FGF1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00115	0.00269	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00114	0.00268	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00114	0.00267	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00113	0.00266	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00113	0.00266	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00113	0.00265	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00112	0.00263	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0011	0.00258	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00109	0.00256	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00108	0.00253	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00106	0.0025	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00106	0.00249	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00105	0.00247	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00105	0.00247	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00105	0.00246	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00105	0.00245	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00104	0.00243	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00103	0.00242	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00103	0.00241	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00102	0.0024	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00102	0.00239	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00101	0.00238	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.001	0.00235	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.001	0.00235	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.001	0.00235	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000998	0.00234	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000991	0.00232	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000984	0.00231	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000981	0.0023	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00098	0.0023	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000979	0.0023	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000975	0.00229	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000971	0.00228	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000971	0.00228	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00097	0.00227	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000965	0.00226	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000963	0.00226	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000957	0.00224	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000955	0.00224	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000955	0.00224	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000953	0.00223	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000943	0.00221	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000937	0.0022	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000928	0.00218	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000927	0.00217	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000923	0.00216	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000911	0.00214	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000911	0.00214	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000906	0.00213	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000902	0.00211	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.0009	0.00211	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000899	0.00211	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000888	0.00208	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000884	0.00207	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000883	0.00207	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000882	0.00207	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000878	0.00206	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000872	0.00205	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000867	0.00203	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000867	0.00203	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000856	0.00201	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000843	0.00198	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000841	0.00197	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000838	0.00196	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000824	0.00193	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000816	0.00191	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000813	0.00191	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000808	0.00189	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000802	0.00188	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000799	0.00187	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000798	0.00187	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000792	0.00186	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000742	0.00174	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000738	0.00173	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000701	0.00164	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000698	0.00164	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000696	0.00163	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000674	0.00158	CbGpPWpGaD
Amlexanox—FGF1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000663	0.00155	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000662	0.00155	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000649	0.00152	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000646	0.00152	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000629	0.00147	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000622	0.00146	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000618	0.00145	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000615	0.00144	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000613	0.00144	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00061	0.00143	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000608	0.00143	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000587	0.00138	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000579	0.00136	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000571	0.00134	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000569	0.00133	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000569	0.00133	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000565	0.00133	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000559	0.00131	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000547	0.00128	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000538	0.00126	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000538	0.00126	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000535	0.00126	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000531	0.00125	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000521	0.00122	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000517	0.00121	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000512	0.0012	CbGpPWpGaD
Amlexanox—IL3—Immune System—EP300—attention deficit hyperactivity disorder	0.000509	0.00119	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000506	0.00119	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000499	0.00117	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000498	0.00117	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000495	0.00116	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000482	0.00113	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000474	0.00111	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000471	0.0011	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000468	0.0011	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000464	0.00109	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00045	0.00105	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000442	0.00104	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000436	0.00102	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000436	0.00102	CbGpPWpGaD
Amlexanox—S100A12—Immune System—EP300—attention deficit hyperactivity disorder	0.000408	0.000957	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000407	0.000953	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000401	0.000939	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000398	0.000934	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000347	0.000813	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00033	0.000774	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000329	0.000772	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000305	0.000716	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000285	0.000668	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EP300—attention deficit hyperactivity disorder	0.000233	0.000547	CbGpPWpGaD
Amlexanox—FGF1—Disease—EP300—attention deficit hyperactivity disorder	0.000215	0.000505	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000211	0.000495	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000184	0.000431	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000175	0.00041	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000162	0.000379	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000151	0.000354	CbGpPWpGaD
